A Phase 2 interventional study of Peripheral magnetic stimulation and Balance training in Diabetic Polyneuropathy, sponsored by Queen Savang Vadhana Memorial Hospital, Thailand. Recruiting at 1 site in Thailand. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Queen Savang Vadhana Memorial Hospital, Thailand · Phase 2, Interventional, and Treatment
This study aims to determine whether peripheral magnetic stimulation (PMS) during balance training in patients with diabetic polyneuropathy reduces fall risk, as measured by balance tests, and lessens disease severity compared to balance training with sham stimulation.
This proof-of-concept study will utilize the Magnetic and Balance Training Activator (MAGBATA), a platform mounted with a magnetic stimulation coil that delivers electromagnetic pulses directly to the plantar surfaces of the feet while patients stand. A racetrack coil (RT-120), connected to the MagPro X100 magnetic stimulator with MagOption (MagVenture, Farum, Denmark), will be used. Parameters for the repetitive peripheral magnetic stimulation (rPMS) protocol will be configured to facilitate sensory input, enhance brain plasticity, and promote axonal regeneration.
This single-center randomized controlled trial will use a two-group parallel design and include 40 patients with diabetic polyneuropathy who meet the eligibility criteria. Participants will be randomly assigned to either the active intervention group or the control group.
The active intervention group will receive a warm-up exercise consisting of 25 repetitions of ankle dorsiflexion with concurrent 10 Hz rPMS applied to the tibialis anterior of each leg. Following the warm-up, participants will stand on the MAGBATA platform and perform 20 cycles of one-leg stance exercises under the supervision of a physiotherapist. Each cycle lasts 20 seconds and consists of 3 seconds of 20 Hz rPMS applied to the plantar surface of the foot while the participant stands on one leg, followed by 12 seconds of rest during which the participant stands on both legs. The same sequence will then be repeated for the other leg. Stimulation intensity will be determined prior to the warm-up. The coil will be placed over the tibialis anterior to determine the minimal contraction threshold (MCT), defined as the lowest intensity that produces a visible contraction. The stimulation intensity will be set at 110% of the MCT for the warm-up exercise and 120% for the treatment during balance exercises.
The control group will receive the same procedure, but with sham stimulation during both the warm-up and one-leg stance phases.
The intervention will consist of 8 sessions, conducted twice per week with at least one day of rest between sessions. Outcome assessments include one-leg stance test (OLST) with eyes open, timed up and go test (TUGT), and short physical performance battery (SPPB); these assessments will be conducted at baseline and after the 4-week intervention. Additionally, a rehabilitation physician, blinded to group allocation, will perform electrophysiologic studies at baseline and week 8 to assess disease severity. These studies will include bilateral measurements of sural nerve amplitude and conduction velocity, tibial compound motor action potential (CMAP) amplitude and conduction velocity, and tibial F-wave latency.
538 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
This study's planned enrollment of 40 is below the median of 68 across 448 interventional studies indexed under Diabetic Neuropathies.
Browse Diabetic Neuropathies studies →Queen Savang Vadhana Memorial Hospital, Thailand is the lead sponsor of 29 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants will undergo a warm-up exercise involving ankle dorsiflexion, with concurrent rPMS applied to the tibialis anterior of each leg. Following the warm-up, participants will stand on the MAGBATA platform and perform one-leg stance exercises while rPMS is applied to the plantar surface of the foot. This procedure will be repeated for the other leg.
Device: Peripheral magnetic stimulation · Behavioral: Balance training
The sham comparator group will receive the same procedure as the interventional group, but with sham stimulation during both the warm-up and one-leg stance exercise.
Behavioral: Balance training · Other: Sham stimulation
During the warm-up exercise, 10-Hz rPMS will be applied to the tibialis anterior with an on-time of 4 seconds (40 pulses per train), followed by an off-time (inter-train interval) of 8 seconds, for a total of 25 trains for each leg. During the one-leg stance exercise, 20-Hz rPMS will be applied to the plantar surface of the standing foot for 3 seconds of on-time (60 pulses per train), followed by 12 seconds of off-time, for a total of 20 trains for each foot. Stimulation intensity will be set at 110% of MCT for the warm-up exercise and 120% of MCT for the treatment during the one-leg stance exercise.
The warm-up exercise consists of 25 repetitions of 4-second active contractions of the tibialis anterior muscle in each leg while seated. Following the warm-up, participants will stand on the MAGBATA platform and perform 20 cycles of one-leg stance exercises under the supervision of a physiotherapist. Each cycle lasts 20 seconds, consisting of 3 seconds of one-leg stance while the other leg is raised about 10 centimeters above the ground, followed by 12 seconds of rest during which the participant stands on both legs, keeping their arms close to their body and hands free. The same sequence will then be repeated for the other leg. To prevent falling, participants will wear a safety belt around the waist, allowing the physiotherapist to assist if they lose balance. Participants will also be allowed to grab the walker positioned in front of them to prevent falling.
During the warm-up exercise, the stimulation coil will be placed perpendicular to the participants' shin. The same parameter settings will be used, except for the intensity, which will be set at 30% of the maximum stimulator output (MSO). Sham stimulation during the one-leg stance exercise is achieved by disconnecting the coil mounted in MAGBATA and placing an alternate coil, connected to the magnetic stimulator placed behind the participants so they can hear a clicking pattern similar to that of the rPMS-BT arm.
One-leg standing balance test (OLST)
Participants stand on the floor with their eyes open and arms relaxed at the sides of the body. They are instructed to lift the opposite foot off the floor, flex the knee to 90 degrees, and position the lifted foot behind the body, maintaining balance on the tested leg for as long as possible. The assessor begins timing when the participant's foot leaves the floor and stops timing if the participant sways, extends either arm to maintain balance, or successfully holds the position for 30 seconds. The test is then repeated on the opposite leg. The durations from each legs are reported in seconds.
Time frame: From enrollment to the end of treatment (week 4).
Timed up and go test (TUGT)
Participants sit on a chair with a seat height between 44 and 47 cm, with their back resting against the backrest. The assessor instructs them to walk to a marked point 3 meters straight ahead and then return to sit on the chair. Timing begins when the participant's back leaves the backrest and stops when they return to the chair and their back touches the backrest. The test is performed twice, and the best performance with shorter duration in seconds, will be recorded.
Time frame: From enrollment to the end of treatment (week 4).
Short physical performance battery (SPPB)
The Short Physical Performance Battery (SPPB) includes three subtests: gait speed, chair stand, and balance. Each test scored from 0 to 4and are summed up to give a total score ranging from 0 to 12. Gait speed: Participants are instructed to walk at their normal pace over a distance of 4 meters. The assessor times each trial from the start of walking until the participant reaches the end. Chair stand test: Participants are instructed to rise from a seated position to standing five times, keeping their arms crossed at chest level. The assessor starts timing when the participant's buttocks leave the chair and stops when they return to the seat after the fifth stand. Balance test on both feet: Participants first stand with feet together for 10 seconds to earn 1 point, then in semi-tandem with the heel beside the mid-foot for 10 seconds to earn another point, and finally in full tandem for 10 seconds to earn 2 points.
Time frame: From enrollment to the end of treatment (week 4).
Nerve conduction study
Nerve conduction study will be performed using the electrodiagnostic unit, Sierra Summit (Cadwell, Kennewick, WA, USA). Bilateral sural and tibial nerves will be tested, measuring parameters including sensory nerve action potential (SNAP) amplitude of the sural nerves, compound motor action potential (CMAP) amplitudes of the tibial nerves, F-wave latency of the tibial nerves. The parameters of each legs are reported separately.
Time frame: From enrollment to week 8.
Plan to share: Yes — De-identified individual-level data related to the primary and secondary outcomes of all participants will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 6 months after publication; for 2 years.
Access criteria: IPD will be shared upon reasonable request by email with researchers conducting similar studies or performing meta-analyses. The process will require approval by the Institutional Review Board (IRB) and may also require a data use agreement.
Started Jun 2025 (actual). Primary completion is estimated for Aug 2026, 14 months after the start.
Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 14 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Savang Vadhana Memorial Hospital, Thailand